November 2023
Ampath | ampath.co.za
Overview
Genetic mutations in FLT3 and NPM1 have significant diagnostic, prognostic, and therapeutic value in patients with acute myeloid leukaemia (AML).
To align with international AML management guidelines, Ampath Genetics now offers:
- PCR-based testing for FLT3-ITD and TKD (D835) mutations
- Quantitative testing for common NPM1 variants (A, B, and D)
- Faster turnaround times than traditional methods
Test Details
✅ FLT3 PCR
- Mnemonic:
FLT3PCR - Purpose:
- Diagnostic and prognostic tool in AML
- Method:
- Qualitative allele-specific PCR
- Fragment analysis
- Detection capability:
- Identifies FLT3-ITDs up to ~500 base pairs (higher sensitivity than NGS)
- Detects only the most common TKD (D835) mutation
- Sample requirements:
- Blood or bone marrow in EDTA tube, minimum 1 mL
- Sample stability:
- 1 week
- Turnaround time:
- 4 working days (from receipt at the National Reference Laboratory)
- Cost (2023):
- R3,631.20 (upfront payment)
✅ NPM1 PCR
- Mnemonic:
NPM1PCR - Purpose:
- Monitoring measurable residual disease (MRD) in NPM1-positive AML
- Method:
- Quantitative PCR
- Targets the most common NPM1 variants: A, B, and D
- Important note:
- Should not be used for diagnostic purposes
- Diagnostic testing should use broader NGS or molecular panels
- Sample requirements:
- Blood or bone marrow in EDTA tube, minimum 3 mL
- Sample stability:
- 72 hours
- Turnaround time:
- 3 working days
- Cost (2023):
- R4,212.80 (upfront payment)
💡 Prices valid until 31 December 2023.
Medical aid scheme rates may differ.
📧 For more information, contact the Molecular Genetics Laboratory:
Email: geneticsmolecular@ampath.co.za
Continue Reading